Navigation Links
Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study
Date:7/22/2009

DOYLESTOWN, Pa., July 22 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., a wholly-owned subsidiary of The Quigley Corporation (Nasdaq: QGLY) www.quigleyco.com, today announced the results from its Phase IIb double-blind, placebo-controlled, study of topical compound QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. The study was completed with fewer than expected evaluable patients with the final and comprehensive conclusions revealing that (i) the compound is safe and well tolerated, and (ii) there were nominal trends, but no statistical differences, between active and placebo groups for the primary and secondary endpoints measuring efficacy by (a) the reduction of pain, (b) symptomatic improvements, (c) improved quality of life and (d) improved sleep.

However, the Company is encouraged by the positive, clinical and statistically significant improvement for efficacy in sural nerve conduction velocity and amplitude unexpectedly found in a sub-set of the patient population, announced in a press release on April 30, 2009. Those data may indicate the potential benefit of this compound as a disease modifying agent which, if validated through additional clinical trials, potentially broadens the therapeutic market opportunity. Additional clinical work would be required and future study considerations might include, a longer duration period to improve patient compliance as well as an assessment of sural nerve function and measures of distal nerve sensory thresholds in the feet to provide more detail to the potential for disease modification. There can be no assurance the Company will undertake additional clinical studies or that the results thereof would lead to a marketable product that can achieve regulatory approvals.

A prel
'/>"/>

SOURCE Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer
2. Dr. Richard Rosenbloom Resumes Services To The Quigley Corporations Pharma Subsidiary
3. Ted Karkus Appointed Interim Chief Executive Officer Of The Quigley Corporation
4. Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board
5. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
6. Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
7. Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Companys Latest Announcement
8. The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
9. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
10. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
11. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Healthcare professionals who ... continuing education at home or on-the-go via laptops, ... 20 brand new, premium Seminar-on-Demand CE courses. The ... over 2,000 hours of CE course ... educational experience. With such a diverse library, there’s ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Two sisters in ... heart damage. Ilina and Medha Krishen use electronic ... sounds of trouble in breathing patterns or heartbeats. ... in Michigan, wanted to find a way to detect ... pollutants. Using an electronic stethoscope, Ilina recorded one breath ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter , ... on Monday officially tightened guidelines for health workers treating Ebola ... and use of a respirator at all times. The ... the tougher rules after two Dallas nurses contracted Ebola while ... States, Liberian national Thomas Eric Duncan. Nina Pham is currently ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is offering ... a damaged mitral valve as the heart continues to ... Abbott Vascular , is designed to treat degenerative ... which the heart’s mitral valve leaflets fail to close ... left ventricle into the left atrium. The heart must ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... Alexandria, Va., USA During the April 5 White House ... willing to work with leaders in Congress from both political ... week. The President stated that he has matched the initial ... for FY11, with differences existing only in areas of priority. ...
... sets of brothers with autism, Johns Hopkins scientists have ... be linked very specifically to the severity of social ... protein 1), is a blueprint for a traffic-directing protein ... cells across which chemical signals flow. , ...
... at North Carolina State University are narrowing the search ... dogs into humans. Humans and dogs don,t just ... similar genetic makeup. Additionally, they share the same types ... genomics at NC State, uses canines as a genetic ...
... AUGUSTA, Ga. Scientists want to protect the optic nerve when ... car wreck. It,s called traumatic optic nerve damage when the ... rattled, resulting in swelling and inflammation that can destroy its major ... and blindness. "The optic nerve is not completely straight so ...
... may join you as the only animal that can re-grow ... chemical cocktail can coax mouse muscle fibers to become the ... regenerating limb. Their study, the first demonstration that mammal muscle ... new limb, appears in the journal ACS Chemical Biology ...
... ORLANDO, FL (April 6, 2011) Breast cancer is the ... women diagnosed each year. Being exposed to estrogen over a ... a woman,s risk of developing the disease. One way ... the breast cancer drug tamoxifen, which interferes with the activity ...
Cached Medicine News:Health News:AADR applauds President Obama's support for maintaining biomedical research in FY11 2Health News:Gene linked to severity of autism's social dysfunction 2Health News:Gene linked to severity of autism's social dysfunction 3Health News:Sniffing out lymphoma by turning dogs into humans 2Health News:Better treatment sought for blinding traumatic optic nerve damage 2Health News:Fox Chase researchers find that fish oil boosts responses to breast cancer drug tamoxifen 2
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014 /PRNewswire/ ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies conducting ... Under the terms of the collaboration, Foundation ... laboratory component of Foundation Medicine,s FoundationOne® assay at the ...
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
(Date:10/20/2014)... ENGLEWOOD, Colo. , Oct. 20, 2014 /PRNewswire/ ... Inc. (NYSE MKT: AMPE), today announced that its ... the clinical and research potential for its novel ... oxidation-reduction potential (ORP) in the body in response ... clinical value of ORP as a clinical marker ...
Breaking Medicine Technology:Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... Calif., March 22, 2012  SurgiCount Medical, Inc., the ... (OTCBB:PSTX, OTCQB:PSTX) today announced that it will be ... compliance software tool for use with its market ... Congress in New Orleans, March 24th - 28th.  ...
...  Anaphore Inc. today announced that it has acquired Shanghai-based ... discovery platform focused on the discovery and development of ... was founded by Raymond Stevens, PhD., of The Scripps ... of Shanghai, China. "The acquisition of RuiYi ...
Cached Medicine Technology:SurgiCount Medical Announces Expanded Functionality of the Safety-Sponge® System 2SurgiCount Medical Announces Expanded Functionality of the Safety-Sponge® System 3Anaphore Announces Acquisition of RuiYi in Shanghai China for GPCR Biologics Drug Discovery Platform 2Anaphore Announces Acquisition of RuiYi in Shanghai China for GPCR Biologics Drug Discovery Platform 3
... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
... OMNI~NEB delivers breakthrough continuous low-flow ... and precise nozzle technology allows for ... with or without Heliox). OMNI~NEB takes ... in both routine and critical care ...
... Graham-Field has been developing ... than 58 years. Our medical-surgical ... reputation for innovation, quality and ... brands include the Labtron® line ...
Medicine Products: